{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:06:04Z","timestamp":1781359564744,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2013\/09295-3"],"award-info":[{"award-number":["2013\/09295-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["(26\/010.002644\/2014 and E- 26\/210.784\/2015)"],"award-info":[{"award-number":["(26\/010.002644\/2014 and E- 26\/210.784\/2015)"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00228-020-02934-9","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T22:02:26Z","timestamp":1592690546000},"page":"1401-1408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin\/paclitaxel-based chemotherapy in patients with gynecologic cancers"],"prefix":"10.1007","volume":"76","author":[{"given":"Luiz Carlos","family":"da Costa Junior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa Louren\u00e7o","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniely Regina","family":"Freitas-Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosane","family":"Vianna-Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7278-0999","authenticated-orcid":false,"given":"Paulo Caleb J\u00fanior Lima","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"issue":"6","key":"2934_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"2934_CR2","unstructured":"B. F. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I (2018) 2018 Global Cancer Observatory: Cancer Today,\u201d International Agency for Research on Cancer. [Online]. Available: https:\/\/gco.iarc.fr\/today. Accessed 16 Jun 2019"},{"issue":"2","key":"2934_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0020-7292(00)00300-3","volume":"70","author":"JL Benedet","year":"2000","unstructured":"Benedet JL, Bender H, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70(2):209\u2013262","journal-title":"Int J Gynecol Obstet"},{"issue":"1","key":"2934_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ygyno.2017.07.134","volume":"147","author":"L Kogan","year":"2017","unstructured":"Kogan L, Laskov I, Amajoud Z, Abitbol J, Yasmeen A, Octeau D, Fatnassi A, Kessous R, Eisenberg N, Lau S, Gotlieb WH, Salvador S (2017) Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol 147(1):30\u201335","journal-title":"Gynecol Oncol"},{"issue":"17","key":"2934_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A et al (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320\u20131329","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"2934_CR6","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194\u20133200","journal-title":"J Clin Oncol"},{"key":"2934_CR7","doi-asserted-by":"publisher","unstructured":"De Castro CL, Carlos L, Junior C, Louren\u00e7o LV, Seba KS, Lopes TS (2019) Impact of gene polymorphisms on the systemic toxicity to paclitaxel\/carboplatin chemotherapy for treatment of gynecologic cancers. Arch Gynecol Obstet. https:\/\/doi.org\/10.1007\/s00404-019-05197-7","DOI":"10.1007\/s00404-019-05197-7"},{"issue":"19","key":"2934_CR8","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33(19):2129\u20132135","journal-title":"J Clin Oncol"},{"issue":"5","key":"2934_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1310\/hpj4905-425","volume":"49","author":"JM Akin","year":"2014","unstructured":"Akin JM, Waddell JA, Solimando DA (2014) Paclitaxel and carboplatin (TC) regimen for ovarian cancer. Hosp Pharm 49(5):425\u2013431","journal-title":"Hosp Pharm"},{"issue":"10","key":"2934_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA (2012) Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 7(10):1713\u20131721","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2934_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","volume":"33","author":"SB Duffull","year":"1997","unstructured":"Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33(3):161\u2013183","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"2934_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrneph.2009.97","volume":"5","author":"V Sahni","year":"2009","unstructured":"Sahni V, Choudhury D, Ahmed Z (2009) Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 5(8):450\u2013462","journal-title":"Nat Rev Nephrol"},{"key":"2934_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.phrs.2016.08.002","volume":"111","author":"C P\u00e9rez-Ram\u00edrez","year":"2016","unstructured":"P\u00e9rez-Ram\u00edrez C, Ca\u00f1adas-Garre M, Alnatsha A, Villar E, Delgado JR, Faus-D\u00e1der MJ, Calleja-Hern\u00e1ndez M (2016) Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res 111:877\u2013884","journal-title":"Pharmacol Res"},{"issue":"15","key":"2934_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2217\/pgs.14.127","volume":"15","author":"V Bos\u00f3","year":"2014","unstructured":"Bos\u00f3 V, Herrero MJ, Santaballa A, Palomar L, Megias JE, de la Cueva H, Rojas L, Marqu\u00e9s MR, Poveda JL, Montalar J, Ali\u00f1o SF (2014) SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics 15(15):1845\u20131858","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2934_CR15","first-page":"1","volume":"8","author":"B Gao","year":"2018","unstructured":"Gao B et al (2018) Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. Sci Rep 8(1):1\u201310","journal-title":"Sci Rep"},{"issue":"1","key":"2934_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-015-0001-5","volume":"16","author":"S Lambrechts","year":"2015","unstructured":"Lambrechts S et al (2015) Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol 16(1):1\u201313","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"2934_CR17","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1158\/1078-0432.CCR-04-1953","volume":"11","author":"R Suk","year":"2005","unstructured":"Suk R et al (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11(4):1534\u20131538","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2934_CR18","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/jcp.26091","volume":"233","author":"F Beheshti","year":"2018","unstructured":"Beheshti F, Hassanian SM, Khazaei M, Hosseini M, ShahidSales S, Hasanzadeh M, Maftouh M, Ferns GA, Avan A (2018) Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer. J Cell Physiol 233(4):2752\u20132758","journal-title":"J Cell Physiol"},{"issue":"2","key":"2934_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-7843.2011.00802.x","volume":"110","author":"TK Bergmann","year":"2012","unstructured":"Bergmann TK, Brasch-Andersen C, Gr\u00e9en H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, Br\u00f8sen K (2012) Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol 110(2):199\u2013204","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"2934_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","volume":"67","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Gr\u00e9en H, Brasch-Andersen C, Mirza MR, Herrstedt J, H\u00f8lund B, du Bois A, Damkier P, Vach W, Brosen K, Peterson C (2011) Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67(7):693\u2013700","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2934_CR21","first-page":"243","volume":"16","author":"YJ He","year":"2016","unstructured":"He YJ et al (2016) Carboplatin\/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. Pharm J 16(3):243\u2013248","journal-title":"Pharm J"},{"issue":"3","key":"2934_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/jcph.587","volume":"56","author":"L Hu","year":"2016","unstructured":"Hu L, Lv QL, Guo Y, Cheng L, Wu NY, Qin CZ, Zhou HH (2016) Genetic variation of CYP3A5 influences paclitaxel\/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients. J Clin Pharmacol 56(3):349\u2013354","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2934_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/pgs-2018-0162","volume":"20","author":"LA Marcath","year":"2019","unstructured":"Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL, Hertz DL (2019) Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. Pharmacogenomics 20(2):95\u2013104","journal-title":"Pharmacogenomics"},{"issue":"1\u20132","key":"2934_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1081\/DMR-120001389","volume":"34","author":"RB Kim","year":"2002","unstructured":"Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34(1\u20132):47\u201354","journal-title":"Drug Metab Rev"},{"issue":"8","key":"2934_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","volume":"2","author":"PJ McHugh","year":"2001","unstructured":"McHugh PJ, Spanswick VJ, Hartley JA (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2(8):483\u2013490","journal-title":"Lancet Oncol"},{"issue":"5","key":"2934_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jcb.20711","volume":"97","author":"CJ McGurk","year":"2006","unstructured":"McGurk CJ, Cummings M, K\u00f6berle B, Hartley JA, Oliver RT, Masters JR (2006) Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 97(5):1121\u20131136","journal-title":"J Cell Biochem"},{"issue":"4","key":"2934_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1590\/S1984-82502014000400004","volume":"50","author":"GF de Sousa","year":"2014","unstructured":"de Sousa GF, Wlodarczyk SR, Monteiro G (2014) Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz J Pharm Sci 50(4):693\u2013702","journal-title":"Braz J Pharm Sci"},{"issue":"5","key":"2934_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2125.2007.02956.x","volume":"64","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema ADR, Huizing MT, Willemse PHB, de Graeff A, Rosing H, Schellens JHM, Beijnen JH, Vermorken JB (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 64(5):622\u2013633","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2934_CR29","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748\u20131756","journal-title":"J Clin Oncol"},{"issue":"3","key":"2934_CR30","first-page":"555","volume":"16","author":"JJ Yu","year":"2000","unstructured":"Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16(3):555\u2013560","journal-title":"Int J Oncol"},{"issue":"2","key":"2934_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/0008-5472.CAN-13-2064","volume":"74","author":"KL Fung","year":"2014","unstructured":"Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2014) MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res 74(2):598\u2013608","journal-title":"Cancer Res"},{"issue":"2","key":"2934_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12033-009-9220-6","volume":"44","author":"TM Sissung","year":"2010","unstructured":"Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44(2):152\u2013167","journal-title":"Mol Biotechnol"},{"issue":"11","key":"2934_CR33","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"N Bahadur","year":"2002","unstructured":"Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6\u03b1-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64(11):1579\u20131589","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"2934_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","volume":"11","author":"E Hustert","year":"2001","unstructured":"Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockm\u00f6ller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):773\u2013779","journal-title":"Pharmacogenetics"},{"issue":"3","key":"2934_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/1568009033481967","volume":"3","author":"M Abal","year":"2005","unstructured":"Abal M, Andreu J, Barasoain I (2005) Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3(3):193\u2013203","journal-title":"Curr Cancer Drug Targets"},{"key":"2934_CR36","doi-asserted-by":"crossref","unstructured":"Reedijk J (1987) The mechanism of action of platinum anti-tumor drugs H3N O \u2014 C CH2 H3N OC \u2019 CH2-. Pure Appl Chem 59(2)181\u2013192","DOI":"10.1351\/pac198759020181"},{"issue":"6","key":"2934_CR37","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00280-017-3314-9","volume":"79","author":"Y Tanabe","year":"2017","unstructured":"Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y (2017) Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol 79(6):1179\u20131186","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2934_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3109\/0284186X.2014.969846","volume":"54","author":"L Eckhoff","year":"2015","unstructured":"Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol (Madr) 54(4):530\u2013537","journal-title":"Acta Oncol (Madr)"},{"issue":"1","key":"2934_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ et al (2019) Drug-induced liver injury. Nat Rev Dis Prim 5(1):58","journal-title":"Nat Rev Dis Prim"},{"issue":"12","key":"2934_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(08)70307-3","volume":"9","author":"KM Field","year":"2008","unstructured":"Field KM, Michael M (2008) Part II: liver function in oncology: towards safer chemotherapy use. Lancet Oncol 9(12):1181\u20131190","journal-title":"Lancet Oncol"},{"issue":"6","key":"2934_CR41","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00280-011-1638-4","volume":"68","author":"T Egawa-Takata","year":"2011","unstructured":"Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, Miyatake T, Fujita M, Yoshino K, Nakashima R, Okazawa M, Tsutsui T, Morishige KI, Kimura T, Yamasaki M, Nishizaki T, Nagamatsu M, Ito K, Asada M, Ogita K, Wakimoto A, Yamamoto T, Nishio Y, Enomoto T (2011) Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy. Cancer Chemother Pharmacol 68(6):1603\u20131610","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2934_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","volume":"66","author":"S Pignata","year":"2008","unstructured":"Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, de Vivo R, Ferrandina G, Gallo C, Perrone F (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66(3):229\u2013236","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2934_CR43","first-page":"13690","volume":"8","author":"L Yang","year":"2015","unstructured":"Yang L, Guo J, Shen Y, Cai J, Xiong Z, Dong W, Min J, Wang Z (2015) Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB 2 -IIB cervical cancer. Int J Clin Exp Med 8(8):13690\u201313698","journal-title":"Int J Clin Exp Med"},{"issue":"27","key":"2934_CR44","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","volume":"28","author":"A Du Bois","year":"2010","unstructured":"Du Bois A et al (2010) Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 28(27):4162\u20134169","journal-title":"J Clin Oncol"},{"issue":"31","key":"2934_CR45","first-page":"18","volume":"9","author":"\u00c1 Garces","year":"2013","unstructured":"Garces \u00c1 et al (2013) Carboplatina e paclitaxel em primeira linha paliativa no tratamento de c\u00e2ncer de colo uterino avan\u00e7ado ou persistente recorrente: an\u00e1lise de uma s\u00e9rie de casos do Instituto Nacional de C\u00e2ncer do Brasil. Rev Bras Oncol Cl\u00edn 9(31):18\u201324","journal-title":"Rev Bras Oncol Cl\u00edn"},{"issue":"4","key":"2934_CR46","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33(4):278\u2013285","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"2934_CR47","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124(6):2333\u20132340","journal-title":"J Clin Invest"},{"key":"2934_CR48","unstructured":"Single Nucleotide Polymorphism database (dbSNP). National Center for Biotechnology. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/snp\/. Accessed 23 July 2019"},{"issue":"3","key":"2934_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.carrev.2006.02.002","volume":"7","author":"JH Houtgraaf","year":"2006","unstructured":"Houtgraaf JH, Versmissen J, van der Giessen WJ (2006) A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 7(3):165\u2013172","journal-title":"Cardiovasc Revasc Med"},{"key":"2934_CR50","doi-asserted-by":"publisher","unstructured":"Zazuli Z et al (2019) SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patients. pp 1\u201317. https:\/\/doi.org\/10.3390\/genes10050364","DOI":"10.3390\/genes10050364"},{"issue":"17","key":"2934_CR51","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2008.19.1718","volume":"27","author":"E Goekkurt","year":"2009","unstructured":"Goekkurt E, al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 27(17):2863\u20132873","journal-title":"J Clin Oncol"},{"issue":"2","key":"2934_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijheh.2010.01.004","volume":"213","author":"S Chen","year":"2010","unstructured":"Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X (2010) Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 213(2):140\u2013145","journal-title":"Int J Hyg Environ Health"},{"issue":"1","key":"2934_CR53","first-page":"54","volume":"10","author":"AV Khrunin","year":"2010","unstructured":"Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharm J 10(1):54\u201361","journal-title":"Pharm J"},{"issue":"3","key":"2934_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clgc.2013.04.007","volume":"11","author":"WD Figg","year":"2013","unstructured":"Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL (2013) Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clin Genitourin Cancer 11(3):229\u2013237","journal-title":"Clin Genitourin Cancer"},{"key":"2934_CR55","doi-asserted-by":"publisher","unstructured":"Liu HE et al (2014) Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients. Biomed Res Int. https:\/\/doi.org\/10.1155\/2014\/937429","DOI":"10.1155\/2014\/937429"},{"issue":"November","key":"2934_CR56","first-page":"7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruot T, Hamadat H, Gottesman MM, Pastan IRA (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Sci York 84(November):7735\u20137738","journal-title":"Sci York"},{"issue":"14","key":"2934_CR57","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1158\/1078-0432.CCR-07-4230","volume":"14","author":"TM Sissung","year":"2008","unstructured":"Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14(14):4543\u20134549","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2934_CR58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115\u2013124","journal-title":"Am J Med Sci"},{"issue":"2","key":"2934_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.sjbs.2010.02.003","volume":"17","author":"SO Rabah","year":"2010","unstructured":"Rabah SO (2010) Acute Taxol nephrotoxicity: histological and ultrastructural studies of mice kidney parenchyma. Saudi J Biol Sci 17(2):105\u2013114","journal-title":"Saudi J Biol Sci"},{"issue":"11","key":"2934_CR60","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490\u20132518","journal-title":"Toxins (Basel)"},{"issue":"6 SUPPL. 1","key":"2934_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0090-4295(99)00451-3","volume":"54","author":"U Vaishampayan","year":"1999","unstructured":"Vaishampayan U, Parchment RE, Jasti BR, Hussain M (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54(6 SUPPL. 1):22\u201329","journal-title":"Urology"},{"key":"2934_CR62","doi-asserted-by":"publisher","unstructured":"Stordal B et al (2012) Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 7(7). https:\/\/doi.org\/10.1371\/journal.pone.0040717","DOI":"10.1371\/journal.pone.0040717"},{"key":"2934_CR63","doi-asserted-by":"crossref","unstructured":"Cao S, Wang C, Ma H, Yin R, Zhu M, Shen W, Dai J, Shu Y, Xu L, Hu Z, Shen H (2015) Genome-wide Association Study on Platinum-induced Hepatotoxicity in Non-Small Cell Lung Cancer Patients. Scientific Reports 5.","DOI":"10.1038\/srep11556"},{"key":"2934_CR64","doi-asserted-by":"crossref","unstructured":"Qian C-Y, Zheng Y, Wang Y, Chen J, Liu J-Y, Zhou H-H, Yin J-Y, Liu Z-Q (2016) Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer Res 35.","DOI":"10.1186\/s40880-016-0145-8"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02934-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T09:07:03Z","timestamp":1650532023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02934-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2934"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02934-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"8 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committees of <i>Instituto Nacional de C\u00e2ncer<\/i> (20406413.6.0000.5274) and <i>Escola Paulista de Medicina<\/i>, <i>Universidade Federal de S\u00e3o Paulo<\/i> (84775518.3.0000.5505).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}